Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BeiGene Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2010-01-01

Employees: 10K

Market Cap: $22.1B

Website: http://www.beigene.com

Clinical Trials

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BGB-30813
Drug: Tislelizumab

First Posted Date: 2023-06-15

Last Posted Date: 2025-06-22

Lead Sponsor: BeiGene

Target Recruit Count: 44

Registration Number: NCT05904496

Locations: 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China

and more 8 locations

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-BGB-11417

First Posted Date: 2023-05-06

Last Posted Date: 2025-04-17

Lead Sponsor: BeiGene

Target Recruit Count: 6

Registration Number: NCT05844111

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Phase 1

Recruiting

Conditions: Refractory Chronic Lymphocytic Leukemia
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Relapsed Chronic Lymphocytic Leukemia
Relapsed Follicular Lymphoma
Relapsed Marginal Zone Lymphoma
Relapse Diffuse Large B Cell Lymphoma
Relapsed Small Lymphocytic Lymphoma
Refractory Follicular Lymphoma
Refractory Marginal Zone Lymphoma

Interventions: Drug: BGB-21447

First Posted Date: 2023-04-25

Last Posted Date: 2025-06-24

Lead Sponsor: BeiGene

Target Recruit Count: 112

Registration Number: NCT05828589

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Mission Cancer and Blood, Waukee, Iowa, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States

and more 35 locations

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Zanubrutinib

First Posted Date: 2023-03-14

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 58

Registration Number: NCT05767398

Locations: 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Phase 2

Recruiting

Conditions: Primary Membranous Nephropathy

Interventions: Drug: Zanubrutinib
Drug: Tacrolimus

First Posted Date: 2023-01-31

Last Posted Date: 2025-06-24

Lead Sponsor: BeiGene

Target Recruit Count: 282

Registration Number: NCT05707377

Locations: 🇷🇺
Medical Company Llc, Grozny, Chechenskaya Respublika, Russian Federation
🇺🇸
Amicis Research Center, Northridge, California, United States
🇺🇸
Stanford University, Palo Alto, California, United States

and more 68 locations

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma
Renal Cell Carcinoma
Melanoma
Non-mucosal Melanoma

Interventions: Drug: BGB-A445
Drug: Tislelizumab

First Posted Date: 2022-12-22

Last Posted Date: 2025-05-01

Lead Sponsor: BeiGene

Target Recruit Count: 202

Registration Number: NCT05661955

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China

and more 15 locations

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Phase 1

Withdrawn

Conditions: Solid Tumors

Interventions: Drug: BGB-B167
Drug: Tislelizumab

First Posted Date: 2022-12-09

Last Posted Date: 2023-11-29

Lead Sponsor: BeiGene

Registration Number: NCT05644626

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Recruiting

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Zanubrutinib

First Posted Date: 2022-12-07

Last Posted Date: 2025-06-22

Lead Sponsor: BeiGene

Target Recruit Count: 111

Registration Number: NCT05640102

Locations: 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 13 locations

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: BGB-A445
Drug: LBL-007
Drug: BGB-15025
Drug: Carboplatin
Drug: Cisplatin
Drug: pemetrexed
Drug: Paclitaxel
Drug: Nab paclitaxel

First Posted Date: 2022-12-02

Last Posted Date: 2025-06-22

Lead Sponsor: BeiGene

Target Recruit Count: 400

Registration Number: NCT05635708

Locations: 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States

and more 61 locations

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Phase 1

Active, not recruiting

Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Interventions: Drug: LBL-007
Drug: Tislelizumab
Drug: Bevacizumab or Bevacizumab biosimilar
Drug: Capecitabine
Drug: 5-Fluorouracil

First Posted Date: 2022-11-08

Last Posted Date: 2025-06-11

Lead Sponsor: BeiGene

Target Recruit Count: 113

Registration Number: NCT05609370

Locations: 🇺🇸
Alaska Oncology and Hematology, Llc, Anchorage, Alaska, United States
🇺🇸
Banner Md Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Toi Clinical Research, Cerritos, California, United States

and more 73 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy